Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic Resection Plus Adjuvant Chemoradiotherapy for cT1b Esophageal Squamous Cell Carcinoma
ChiCTR2500100590Phase 2Recruiting
- Sponsor
- Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Primary endpoints: 3-year overall survival and Toxicity. Started Apr 2025; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500100590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100590.